Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Doppl
Lausanne, Vaud, Switzerlanddoppl.ch ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Doppl has validated its Bionoid test in cystic fibrosis patients, demonstrating the ability to identify effective treatments that are reimbursable by health insurance. The company is expanding clinical proof points from one to eleven cystic fibrosis patients and is negotiating contracts with oncology departments. Its technology is recognized by hospitals, pharma, and biotech companies for enabling personalized medicine through advanced organoid models.
- Therapeutic areas
- OncologyPulmonologyRare DiseasesImmunology
- Modalities
- Organoid-based modelsDevice (organs-on-a-chip)Non-pharmacological therapy (personalized medicine platform)
- Industry
- Drug Discovery Services
02
Partnerships
EPFL (licensing agreement covering three patents for the Bionoid test/organoids culture recipes)Hospitals & pharmaceutical/biotech companies as clients/users of the technology
Beyond the preview
Go deeper on Doppl.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doppl.